Clinical Trial Update: QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer [Phase 2, Phase 3]

View source ↗

Summary

A multicenter Phase 2/3 clinical trial evaluating intravesical Bacillus Calmette-Guerin in combination with ALT-803 (N-803) for BCG-unresponsive high-grade non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ALT-803 (Interleukin-15 super-agonist)
• Bacillus Calmette-Guerin (Bacillus Calmette-Guerin)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Bladder Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING